Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel
The aim of the study was to retrospectively investigate the association between chemotherapy-induced neutropenia and survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line docetaxel treatment. Docetaxel-induced neutropenia is associated with better overall...
Gespeichert in:
| Veröffentlicht in: | Clinical genitourinary cancer 2018-08, Vol.16 (4), p.318-324 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 324 |
|---|---|
| container_issue | 4 |
| container_start_page | 318 |
| container_title | Clinical genitourinary cancer |
| container_volume | 16 |
| creator | Buttigliero, Consuelo Tucci, Marcello Vignani, Francesca Di Stefano, Rosario F. Leone, Gianmarco Zichi, Clizia Pignataro, Daniele Lacidogna, Gaetano Guglielmini, Pamela Numico, Gianmauro Scagliotti, Giorgio V. Di Maio, Massimo |
| description | The aim of the study was to retrospectively investigate the association between chemotherapy-induced neutropenia and survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line docetaxel treatment. Docetaxel-induced neutropenia is associated with better overall and progression-free survival in mCRPC. These findings support the hypothesis that chemotherapy-induced neutropenia might be a surrogate indicator of the biological activity of chemotherapy in patients with mCRPC.
Neutropenia is a common side effect associated with docetaxel use. We retrospectively investigated the association between chemotherapy-induced neutropenia and survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line docetaxel.
Metastatic castration-resistant prostate cancer patients treated with first-line docetaxel, with known neutrophils value 10 days after first administration, were included in this retrospective analysis. Neutropenia was categorized in Grade 0 to 1 (G0-1), Grade 2 to 3 (G2-3), and Grade 4 (G4). Outcome measures were progression-free survival (PFS) and overall survival (OS).
Eighty patients were analyzed. Median PFS was 5.4 months in patients with G0-1 neutropenia, 6.9 months with G2-3 neutropenia (hazard ratio [HR] vs. G0-1, 0.69; 95% confidence interval [CI], 0.35-1.35; P = .27) and 9.5 months with G4 neutropenia (HR vs. G0-1, 0.30; 95% CI, 0.16-0.57; P < .0001). Median OS was 11.6 months in patients with G0-1 neutropenia, 25.5 months in patients with G2-3 neutropenia (HR vs. G0-1, 0.36; 95% CI, 0.16-0.80; P = .012) and 39.3 months in patients with G4 neutropenia (HR vs. G0-1, 0.19; 95% CI, 0.09-0.41; P |
| doi_str_mv | 10.1016/j.clgc.2018.05.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2050488024</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1558767318303422</els_id><sourcerecordid>2050488024</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-5e0a972bf01ad666f4b2d5fdfc37c4f0c1fa9af6d4fb5b2165937a42f50223373</originalsourceid><addsrcrecordid>eNp9UcFu1DAUjBCIlsIPcEA-ckl4dmInkbigLYVKC61QEUfLsZ9ZrxJ7sR1Ev4JfxqstHDl5_N7MSG-mql5SaChQ8Wbf6Pm7bhjQoQHeAIhH1Tkd26EGMbDHBXM-1L3o27PqWUp7gI7THp5WZ2wchOhGfl793uxwCXmHUR3u62tvVo2GfMY1x3BA7xRR3pCbNeuwIHGe3Krs0OdEvrm8I58wq5TLSJNNAbGg4OsvmFyZ-kxuYziusWy9xkjuIpafOYmvXEy53jqP5DLo4vQL5-fVE6vmhC8e3ovq69X7u83Henvz4XrzblvrlotccwQ19myyQJURQthuYoZbY3Xb686CplaNygrT2YlPjAo-tr3qmOXAWNv27UX1-uR7iOHHiinLxSWN86w8hjVJBhy6YQDWFSo7UXU5JkW08hDdouK9pCCPRci9PBYhj0VI4LIUUUSvHvzXaUHzT_I3-UJ4eyJgufKnwyiTLsGW9F1EnaUJ7n_-fwBaXpyR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2050488024</pqid></control><display><type>article</type><title>Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Buttigliero, Consuelo ; Tucci, Marcello ; Vignani, Francesca ; Di Stefano, Rosario F. ; Leone, Gianmarco ; Zichi, Clizia ; Pignataro, Daniele ; Lacidogna, Gaetano ; Guglielmini, Pamela ; Numico, Gianmauro ; Scagliotti, Giorgio V. ; Di Maio, Massimo</creator><creatorcontrib>Buttigliero, Consuelo ; Tucci, Marcello ; Vignani, Francesca ; Di Stefano, Rosario F. ; Leone, Gianmarco ; Zichi, Clizia ; Pignataro, Daniele ; Lacidogna, Gaetano ; Guglielmini, Pamela ; Numico, Gianmauro ; Scagliotti, Giorgio V. ; Di Maio, Massimo</creatorcontrib><description>The aim of the study was to retrospectively investigate the association between chemotherapy-induced neutropenia and survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line docetaxel treatment. Docetaxel-induced neutropenia is associated with better overall and progression-free survival in mCRPC. These findings support the hypothesis that chemotherapy-induced neutropenia might be a surrogate indicator of the biological activity of chemotherapy in patients with mCRPC.
Neutropenia is a common side effect associated with docetaxel use. We retrospectively investigated the association between chemotherapy-induced neutropenia and survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line docetaxel.
Metastatic castration-resistant prostate cancer patients treated with first-line docetaxel, with known neutrophils value 10 days after first administration, were included in this retrospective analysis. Neutropenia was categorized in Grade 0 to 1 (G0-1), Grade 2 to 3 (G2-3), and Grade 4 (G4). Outcome measures were progression-free survival (PFS) and overall survival (OS).
Eighty patients were analyzed. Median PFS was 5.4 months in patients with G0-1 neutropenia, 6.9 months with G2-3 neutropenia (hazard ratio [HR] vs. G0-1, 0.69; 95% confidence interval [CI], 0.35-1.35; P = .27) and 9.5 months with G4 neutropenia (HR vs. G0-1, 0.30; 95% CI, 0.16-0.57; P < .0001). Median OS was 11.6 months in patients with G0-1 neutropenia, 25.5 months in patients with G2-3 neutropenia (HR vs. G0-1, 0.36; 95% CI, 0.16-0.80; P = .012) and 39.3 months in patients with G4 neutropenia (HR vs. G0-1, 0.19; 95% CI, 0.09-0.41; P < .0001). In multivariate analysis, the occurrence of severe neutropenia showed a statistically significant association with OS (HR G4 vs. G0-1, 0.14; 95% CI, 0.03-0.67; P = .013; HR G2-3 vs. G0-1, 0.42; 95% CI, 0.11-1.57; P = .20) and PFS (HR G4 vs. G0-1, 0.28; 95% CI, 0.09-0.86; P = .03; HR G2-3 vs. G0-1, 1.07; 95% CI, 0.38-2.96; P = .90).
Docetaxel-induced neutropenia is associated with better survival of mCRPC.</description><identifier>ISSN: 1558-7673</identifier><identifier>EISSN: 1938-0682</identifier><identifier>DOI: 10.1016/j.clgc.2018.05.006</identifier><identifier>PMID: 29866495</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Aged, 80 and over ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Blood Cell Count ; Chemotherapy induced neutropenia ; Docetaxel - administration & dosage ; Docetaxel - adverse effects ; Humans ; Male ; Metastatic castration resistant prostate cancer ; Middle Aged ; Neutropenia - chemically induced ; Overall survival ; Patient Outcome Assessment ; Prognosis ; Progression-Free Survival ; Prostatic Neoplasms, Castration-Resistant - drug therapy ; Retrospective Studies ; Survival Analysis ; Treatment Outcome</subject><ispartof>Clinical genitourinary cancer, 2018-08, Vol.16 (4), p.318-324</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-5e0a972bf01ad666f4b2d5fdfc37c4f0c1fa9af6d4fb5b2165937a42f50223373</citedby><cites>FETCH-LOGICAL-c356t-5e0a972bf01ad666f4b2d5fdfc37c4f0c1fa9af6d4fb5b2165937a42f50223373</cites><orcidid>0000-0001-8906-3785 ; 0000-0002-2877-2518 ; 0000-0001-8981-4155</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29866495$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buttigliero, Consuelo</creatorcontrib><creatorcontrib>Tucci, Marcello</creatorcontrib><creatorcontrib>Vignani, Francesca</creatorcontrib><creatorcontrib>Di Stefano, Rosario F.</creatorcontrib><creatorcontrib>Leone, Gianmarco</creatorcontrib><creatorcontrib>Zichi, Clizia</creatorcontrib><creatorcontrib>Pignataro, Daniele</creatorcontrib><creatorcontrib>Lacidogna, Gaetano</creatorcontrib><creatorcontrib>Guglielmini, Pamela</creatorcontrib><creatorcontrib>Numico, Gianmauro</creatorcontrib><creatorcontrib>Scagliotti, Giorgio V.</creatorcontrib><creatorcontrib>Di Maio, Massimo</creatorcontrib><title>Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel</title><title>Clinical genitourinary cancer</title><addtitle>Clin Genitourin Cancer</addtitle><description>The aim of the study was to retrospectively investigate the association between chemotherapy-induced neutropenia and survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line docetaxel treatment. Docetaxel-induced neutropenia is associated with better overall and progression-free survival in mCRPC. These findings support the hypothesis that chemotherapy-induced neutropenia might be a surrogate indicator of the biological activity of chemotherapy in patients with mCRPC.
Neutropenia is a common side effect associated with docetaxel use. We retrospectively investigated the association between chemotherapy-induced neutropenia and survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line docetaxel.
Metastatic castration-resistant prostate cancer patients treated with first-line docetaxel, with known neutrophils value 10 days after first administration, were included in this retrospective analysis. Neutropenia was categorized in Grade 0 to 1 (G0-1), Grade 2 to 3 (G2-3), and Grade 4 (G4). Outcome measures were progression-free survival (PFS) and overall survival (OS).
Eighty patients were analyzed. Median PFS was 5.4 months in patients with G0-1 neutropenia, 6.9 months with G2-3 neutropenia (hazard ratio [HR] vs. G0-1, 0.69; 95% confidence interval [CI], 0.35-1.35; P = .27) and 9.5 months with G4 neutropenia (HR vs. G0-1, 0.30; 95% CI, 0.16-0.57; P < .0001). Median OS was 11.6 months in patients with G0-1 neutropenia, 25.5 months in patients with G2-3 neutropenia (HR vs. G0-1, 0.36; 95% CI, 0.16-0.80; P = .012) and 39.3 months in patients with G4 neutropenia (HR vs. G0-1, 0.19; 95% CI, 0.09-0.41; P < .0001). In multivariate analysis, the occurrence of severe neutropenia showed a statistically significant association with OS (HR G4 vs. G0-1, 0.14; 95% CI, 0.03-0.67; P = .013; HR G2-3 vs. G0-1, 0.42; 95% CI, 0.11-1.57; P = .20) and PFS (HR G4 vs. G0-1, 0.28; 95% CI, 0.09-0.86; P = .03; HR G2-3 vs. G0-1, 1.07; 95% CI, 0.38-2.96; P = .90).
Docetaxel-induced neutropenia is associated with better survival of mCRPC.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Blood Cell Count</subject><subject>Chemotherapy induced neutropenia</subject><subject>Docetaxel - administration & dosage</subject><subject>Docetaxel - adverse effects</subject><subject>Humans</subject><subject>Male</subject><subject>Metastatic castration resistant prostate cancer</subject><subject>Middle Aged</subject><subject>Neutropenia - chemically induced</subject><subject>Overall survival</subject><subject>Patient Outcome Assessment</subject><subject>Prognosis</subject><subject>Progression-Free Survival</subject><subject>Prostatic Neoplasms, Castration-Resistant - drug therapy</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>1558-7673</issn><issn>1938-0682</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UcFu1DAUjBCIlsIPcEA-ckl4dmInkbigLYVKC61QEUfLsZ9ZrxJ7sR1Ev4JfxqstHDl5_N7MSG-mql5SaChQ8Wbf6Pm7bhjQoQHeAIhH1Tkd26EGMbDHBXM-1L3o27PqWUp7gI7THp5WZ2wchOhGfl793uxwCXmHUR3u62tvVo2GfMY1x3BA7xRR3pCbNeuwIHGe3Krs0OdEvrm8I58wq5TLSJNNAbGg4OsvmFyZ-kxuYziusWy9xkjuIpafOYmvXEy53jqP5DLo4vQL5-fVE6vmhC8e3ovq69X7u83Henvz4XrzblvrlotccwQ19myyQJURQthuYoZbY3Xb686CplaNygrT2YlPjAo-tr3qmOXAWNv27UX1-uR7iOHHiinLxSWN86w8hjVJBhy6YQDWFSo7UXU5JkW08hDdouK9pCCPRci9PBYhj0VI4LIUUUSvHvzXaUHzT_I3-UJ4eyJgufKnwyiTLsGW9F1EnaUJ7n_-fwBaXpyR</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Buttigliero, Consuelo</creator><creator>Tucci, Marcello</creator><creator>Vignani, Francesca</creator><creator>Di Stefano, Rosario F.</creator><creator>Leone, Gianmarco</creator><creator>Zichi, Clizia</creator><creator>Pignataro, Daniele</creator><creator>Lacidogna, Gaetano</creator><creator>Guglielmini, Pamela</creator><creator>Numico, Gianmauro</creator><creator>Scagliotti, Giorgio V.</creator><creator>Di Maio, Massimo</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8906-3785</orcidid><orcidid>https://orcid.org/0000-0002-2877-2518</orcidid><orcidid>https://orcid.org/0000-0001-8981-4155</orcidid></search><sort><creationdate>201808</creationdate><title>Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel</title><author>Buttigliero, Consuelo ; Tucci, Marcello ; Vignani, Francesca ; Di Stefano, Rosario F. ; Leone, Gianmarco ; Zichi, Clizia ; Pignataro, Daniele ; Lacidogna, Gaetano ; Guglielmini, Pamela ; Numico, Gianmauro ; Scagliotti, Giorgio V. ; Di Maio, Massimo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-5e0a972bf01ad666f4b2d5fdfc37c4f0c1fa9af6d4fb5b2165937a42f50223373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Blood Cell Count</topic><topic>Chemotherapy induced neutropenia</topic><topic>Docetaxel - administration & dosage</topic><topic>Docetaxel - adverse effects</topic><topic>Humans</topic><topic>Male</topic><topic>Metastatic castration resistant prostate cancer</topic><topic>Middle Aged</topic><topic>Neutropenia - chemically induced</topic><topic>Overall survival</topic><topic>Patient Outcome Assessment</topic><topic>Prognosis</topic><topic>Progression-Free Survival</topic><topic>Prostatic Neoplasms, Castration-Resistant - drug therapy</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buttigliero, Consuelo</creatorcontrib><creatorcontrib>Tucci, Marcello</creatorcontrib><creatorcontrib>Vignani, Francesca</creatorcontrib><creatorcontrib>Di Stefano, Rosario F.</creatorcontrib><creatorcontrib>Leone, Gianmarco</creatorcontrib><creatorcontrib>Zichi, Clizia</creatorcontrib><creatorcontrib>Pignataro, Daniele</creatorcontrib><creatorcontrib>Lacidogna, Gaetano</creatorcontrib><creatorcontrib>Guglielmini, Pamela</creatorcontrib><creatorcontrib>Numico, Gianmauro</creatorcontrib><creatorcontrib>Scagliotti, Giorgio V.</creatorcontrib><creatorcontrib>Di Maio, Massimo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical genitourinary cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buttigliero, Consuelo</au><au>Tucci, Marcello</au><au>Vignani, Francesca</au><au>Di Stefano, Rosario F.</au><au>Leone, Gianmarco</au><au>Zichi, Clizia</au><au>Pignataro, Daniele</au><au>Lacidogna, Gaetano</au><au>Guglielmini, Pamela</au><au>Numico, Gianmauro</au><au>Scagliotti, Giorgio V.</au><au>Di Maio, Massimo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel</atitle><jtitle>Clinical genitourinary cancer</jtitle><addtitle>Clin Genitourin Cancer</addtitle><date>2018-08</date><risdate>2018</risdate><volume>16</volume><issue>4</issue><spage>318</spage><epage>324</epage><pages>318-324</pages><issn>1558-7673</issn><eissn>1938-0682</eissn><abstract>The aim of the study was to retrospectively investigate the association between chemotherapy-induced neutropenia and survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line docetaxel treatment. Docetaxel-induced neutropenia is associated with better overall and progression-free survival in mCRPC. These findings support the hypothesis that chemotherapy-induced neutropenia might be a surrogate indicator of the biological activity of chemotherapy in patients with mCRPC.
Neutropenia is a common side effect associated with docetaxel use. We retrospectively investigated the association between chemotherapy-induced neutropenia and survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line docetaxel.
Metastatic castration-resistant prostate cancer patients treated with first-line docetaxel, with known neutrophils value 10 days after first administration, were included in this retrospective analysis. Neutropenia was categorized in Grade 0 to 1 (G0-1), Grade 2 to 3 (G2-3), and Grade 4 (G4). Outcome measures were progression-free survival (PFS) and overall survival (OS).
Eighty patients were analyzed. Median PFS was 5.4 months in patients with G0-1 neutropenia, 6.9 months with G2-3 neutropenia (hazard ratio [HR] vs. G0-1, 0.69; 95% confidence interval [CI], 0.35-1.35; P = .27) and 9.5 months with G4 neutropenia (HR vs. G0-1, 0.30; 95% CI, 0.16-0.57; P < .0001). Median OS was 11.6 months in patients with G0-1 neutropenia, 25.5 months in patients with G2-3 neutropenia (HR vs. G0-1, 0.36; 95% CI, 0.16-0.80; P = .012) and 39.3 months in patients with G4 neutropenia (HR vs. G0-1, 0.19; 95% CI, 0.09-0.41; P < .0001). In multivariate analysis, the occurrence of severe neutropenia showed a statistically significant association with OS (HR G4 vs. G0-1, 0.14; 95% CI, 0.03-0.67; P = .013; HR G2-3 vs. G0-1, 0.42; 95% CI, 0.11-1.57; P = .20) and PFS (HR G4 vs. G0-1, 0.28; 95% CI, 0.09-0.86; P = .03; HR G2-3 vs. G0-1, 1.07; 95% CI, 0.38-2.96; P = .90).
Docetaxel-induced neutropenia is associated with better survival of mCRPC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29866495</pmid><doi>10.1016/j.clgc.2018.05.006</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-8906-3785</orcidid><orcidid>https://orcid.org/0000-0002-2877-2518</orcidid><orcidid>https://orcid.org/0000-0001-8981-4155</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1558-7673 |
| ispartof | Clinical genitourinary cancer, 2018-08, Vol.16 (4), p.318-324 |
| issn | 1558-7673 1938-0682 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2050488024 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Blood Cell Count Chemotherapy induced neutropenia Docetaxel - administration & dosage Docetaxel - adverse effects Humans Male Metastatic castration resistant prostate cancer Middle Aged Neutropenia - chemically induced Overall survival Patient Outcome Assessment Prognosis Progression-Free Survival Prostatic Neoplasms, Castration-Resistant - drug therapy Retrospective Studies Survival Analysis Treatment Outcome |
| title | Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T21%3A48%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemotherapy-Induced%20Neutropenia%20and%20Outcome%20in%20Patients%20With%20Metastatic%20Castration-Resistant%20Prostate%20Cancer%20Treated%20With%20First-Line%20Docetaxel&rft.jtitle=Clinical%20genitourinary%20cancer&rft.au=Buttigliero,%20Consuelo&rft.date=2018-08&rft.volume=16&rft.issue=4&rft.spage=318&rft.epage=324&rft.pages=318-324&rft.issn=1558-7673&rft.eissn=1938-0682&rft_id=info:doi/10.1016/j.clgc.2018.05.006&rft_dat=%3Cproquest_cross%3E2050488024%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2050488024&rft_id=info:pmid/29866495&rft_els_id=S1558767318303422&rfr_iscdi=true |